Calorically restricted diets decrease PCSK9 in overweight adolescents
A E Levenson, C E Milliren, S B Biddinger, C B Ebbeling, H A Feldman, D S Ludwig, S D de Ferranti, A E Levenson, C E Milliren, S B Biddinger, C B Ebbeling, H A Feldman, D S Ludwig, S D de Ferranti
Abstract
Background and aims: Nutritional therapy is the first line approach to treatment of hyperlipidemia in childhood. Proprotein convertase subtilisin kexin type 9 (PCSK9) is a key regulator of plasma cholesterol levels and a target of novel lipid-lowering pharmacotherapies. We examined the effects of an intensive nutritional intervention on PCSK9 levels in overweight adolescents with cardiovascular disease (CVD) risk factors.
Methods and results: Twenty seven obese and overweight adolescents with CVD risk factors were assigned to either a low fat or low glycemic load diet. During an 8-week "Intensive Phase," assigned meals were delivered to the home, and all participants received weekly in-person home nutrition counseling and phone calls. The subjects then underwent a 4-month "Maintenance Phase" without food provision and with no in-person contact. Anthropometric measurements, laboratory data, and serum PCSK9 protein levels were measured at baseline, 8 weeks, and 6 months. PCSK9 decreased by 16.5% at 8 weeks (201.2 ± 56.3 vs 165.6 ± 58.4 ng/mL; p < 0.001); PCSK9 levels returned to baseline levels at 6 months, after the Maintenance Phase. Change in PCSK9 was associated with change in fasting insulin, HOMA-IR, and AUC insulin, independent of weight loss.
Conclusions: PCSK9 decreased in youth participating in an intensive dietary intervention. Change in HOMA-IR was associated with change in PCSK9, independent of weight loss, suggesting an important relationship with insulin sensitivity. ClinicalTrials.gov Identifier: NCT01080339.
Keywords: Adolescents; Dyslipidemia; Nutritional Therapy; Obesity; PCSK9.
Conflict of interest statement
CONFLICT OF INTEREST
Dr. Ludwig reported receiving royalties for books about nutrition and obesity. Dr. de Ferranti has received royalties for UpToDate topics on treatment of pediatric lipid disorders.
Copyright © 2017 The Italian Society of Diabetology, the Italian Society for the Study of Atherosclerosis, the Italian Society of Human Nutrition, and the Department of Clinical Medicine and Surgery, Federico II University. Published by Elsevier B.V. All rights reserved.
Figures


Figure 2
Change in PCSK9 from baseline…
Figure 2
Change in PCSK9 from baseline to 8 weeks (“ Intensive Phase ”, X…
Figure 3
Correlation between change in (ln)PCSK9…
Figure 3
Correlation between change in (ln)PCSK9 and change in HOMA-IR and fasting insulin at…


Source: PubMed
Tulevat kliiniset tutkimukset
-
NCT07646600Ei vielä rekrytointia
-
NCT07646613Rekrytointi
-
NCT07646626RekrytointiPaikallisesti edenneet (ei leikattavissa) tai metastaattiset kiinteät kasvaimet
-
NCT07646639RekrytointiPeräsuolen syöpä | Sädehoito
-
NCT07646652Ei vielä rekrytointia
-
NCT07646678Ei vielä rekrytointiaIdiopaattinen hypersomnia | Narkolepsia tyyppi 1 | Narkolepsia tyyppi 2
-
NCT07646691Ei vielä rekrytointiaKrooniset keuhkosairaudet
-
NCT07646730RekrytointiPostoperatiiviset komplikaatiot | Rintakehäkirurgia | Perioperative Monitoring
-
NCT07646782RekrytointiSydän-ja verisuonitaudit | Neoplasmat | Kuolleisuus | Ammattitaudit | Kognitiivinen toimintahäiriö | Metabolinen oireyhtymä | Dementia | Hauras | Ikääntyminen | Tuki- ja liikuntaelinten sairaus
-
NCT07646808Ei vielä rekrytointia
-
NCT07646821Ei vielä rekrytointiaAtsasitidiini | MDS/AML | Ropeginterferon | Alfa-2b